54 results about "Bronchus" patented technology

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention belongs to the technical field of biological medicine, and particularly relates to application of corynebacterium casei in preparation of medicine for preventing and treating lung injury. By constructing a radon inhalation-induced lung injury mouse model, after exposure at different radon levels, the weight of a mouse is reduced, the lung coefficient is increased, the tidal volume of the lung, the ventilation volume per minute and the maximum inspiration flow are reduced, the respiratory function is inhibited, the alveolar cavity of the mouse is abnormally expanded, the pulmonary septum is thickened and fractured, and more fibrin exudation is accompanied; the traditional Chinese medicine composition can be used for effectively inhibiting pulmonary fibrosis and lung injury due to obvious inflammatory infiltration beside bronchial tubes, extravasated blood in small blood vessels and lung tissue collagen deposition, and can be used for gavage of corynebacterium casei to effectively inhibit the above phenomena. Therefore, the corynebacterium casei can be used for preventing and treating lung injury, especially lung injury caused by radon exposure.

The invention discloses a lung drainage basin map construction method, which comprises the steps of obtaining point cloud data of bronchus, extracting a center line of the bronchus by using the point cloud data, and performing key point identification on the center line to obtain an undirected graph; firstly marking a main airway and first and second branches of the bronchial central line by using the undirected graph, and then marking the rest branches of the bronchial central line to obtain a marked bronchial central line; carrying out voxel distribution on the marked bronchial central line to obtain a first bronchial image; on the basis of the first bronchial image, a virtual branch is generated for the bronchial tube, and a second bronchial image is obtained; and calculating the average sectional area # imgabs0 # of each bronchus in the second bronchus image, calculating the weight # imgabs2 # of the bronchus in the lung drainage basin according to the average sectional area # imgabs1 #, and finally generating a lung drainage basin map in combination with the weight # imgabs3 #. The influence of bronchus thickness on the lung drainage basin is fully considered, and a more accurate lung drainage basin map can be generated.

The invention relates to the field of medical image processing, in particular to a pulmonary nodule natural orifice optimal path intelligent planning system which comprises a data preprocessing module, a bronchus three-dimensional segmentation module, a pulmonary nodule segmentation module, a differential geometric path search module, a path evaluation module and a doctor interaction module. The differential geometric path search module comprises a Riemannian curvature flow modeling unit, a multi-scale Gaussian curvature constraint unit and a geodesic curvature self-adaptive correction unit, can model bronchus into a Riemannian manifold, applies curvature flow optimization, and combines a multi-scale decomposition strategy and a geodesic theory to obtain a geodesic curvature self-adaptive correction model; precise description and optimal path planning of bronchial geometrical characteristics are realized, the path evaluation module provides multi-dimensional evaluation of blood vessel avoidance, diameter adaptation and curvature safety, and the doctor interaction module supports three-dimensional visualization and real-time path editing. The problem that a traditional Euclidean space algorithm is insufficient in description of complex forms of bronchus is solved by introducing a differential geometry theory.

The invention provides an insertion part and an endoscope, relates to the technical field of endoscopes, and solves the problem of large displacement of the insertion part relative to a target focus due to respiratory movement in the prior art. The endoscope is provided with an insertion part, and a working channel, a first fluid channel and a second fluid channel which are mutually independent and extend from the near end to the far end are arranged in a front end assembly of the insertion part; a to-be-fixed area integrally adjacent to the front end assembly is arranged on the outer peripheral wall of the insertion part; the first fluid channel conveys the hydrogel to an outlet located in a to-be-fixed area to be discharged; the second fluid channel conveys the hydrogel degradation agent to an outlet located in a to-be-fixed area to be discharged; an outlet of the working channel is located in the far end face of the insertion part and used for instrument penetrating and negative pressure suction. The space between the insertion part and the bronchus can be filled with hydrogel through the first fluid channel so that the insertion part can be temporarily fixed to the position, adjacent to the focus, in the bronchus, and therefore the displacement degree between the insertion part and the focus can be reduced in the breathing process of a patient.

The present invention belongs to the field of biomedicine technology, and in particular to the application of Corynebacterium casei in the preparation of medicines for preventing and treating lung injury. The present invention constructs a mouse model of lung injury caused by radon inhalation and finds that after exposure to different radon levels, the mice lose weight, increase the lung coefficient, reduce the lung tidal volume, minute ventilation and maximum inspiratory flow, and their respiratory function is inhibited. The alveolar cavity of the mice is abnormally expanded, the lung septum is thickened and fractured, accompanied by more fibrin exudation, obvious inflammatory infiltration appears near the bronchus, congestion occurs in small blood vessels, and collagen deposition in lung tissue can lead to the occurrence of pulmonary fibrosis, causing lung injury. Oral administration of Corynebacterium casei can effectively inhibit the above-mentioned phenomenon. Therefore, Corynebacterium casei can be used for the prevention and treatment of lung injury, especially lung injury caused by radon exposure.

Respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) are commonly treated with β2-adrenergic receptor agonists that activate intracellular signaling pathways to induce airway relaxation. However, current therapies are limited by progressive receptor desensitization, or tachyphylaxis, largely attributed to β-arrestin recruitment. This desensitization reduces therapeutic efficacy over time and complicates long-term disease management, resulting in suboptimal outcomes for patients who rely on bronchodilators for daily symptom control. Disclosed herein are pharmaceutical compositions comprising biased agonists and their methods of use, which minimally activate recruitment of beta-arrestin2.

The invention discloses a segmentation modeling method for improving bronchial branch identification precision, and belongs to the technical field of medical image processing and respiratory tract three-dimensional reconstruction. According to the method, high-resolution acquisition is performed on a respiratory tract CT image, and preliminary segmentation of a tracheal tree is completed in combination with gray threshold setting and a region growing algorithm; and a reference line is introduced at the bifurcation, and dynamic region growth based on density gradient is adopted, so that refined identification of the sixth-level bronchial branch is realized. And then carrying out iteration correction on the generated model for multiple times, manually comparing anatomical features to delete pseudo branches and complement missing branches, and completing smoothing and NURBS curved surface construction in Geomagic software. And finally, splicing and fusing the bronchial branch model and an independently generated upper respiratory tract model to obtain a complete three-dimensional respiratory tract combination model, and ensuring that the error between the three-dimensional respiratory tract combination model and an original CT image is controlled within 0.8 mm through deviation analysis. According to the method, the recognition precision of the fine bronchial branches can be remarkably improved, the defect of misrecognition or missing division of traditional threshold segmentation is overcome, and the obtained three-dimensional model can be used for aerosol drug deposition simulation, respiratory system disease diagnosis, surgical planning and design and evaluation of personalized inhalation devices.

Provided is a nitrile derivative compound represented by formula (I), its stereoisomers, deuterated compounds, cocrystals, solvates or pharmaceutically acceptable salts, with each group as defined in the specification. The compound has dipeptidyl peptidase 1 inhibitory activity and can be used for preparing drugs for treating diseases including airway obstructive diseases, bronchodilation, cystic fibrosis, asthma, emphysema and chronic obstructive pulmonary disease, etc.

The invention discloses a broncholung lavage fluid composition for treating non-small cell lung cancer, and relates to the technical field of cancer treatment. The preparation method of the bronchus lung lavage fluid composition for treating the non-small cell lung cancer comprises the following steps: S1, performing metagenome sequencing on a BALF sample, S2, grouping by R / NR based on differential strains obtained in S1 to obtain core bacteria, performing single-strain Kaplan-Meier survival analysis on the strains, and determining the survival rate of the single-strain Kaplan-Meier to obtain the bronchus lung lavage fluid composition for treating the non-small cell lung cancer. Finally, seven key microorganisms, namely bronchopulmonary lavage fluid combinations, which are remarkably related to immunotherapy PFS are locked; s3, determining the relationship between the seven key BALF bacteria and the existing immune therapeutic effect marker; and S4, verifying the generation conditions of IL6, IL8 and RANTES cytokines promoted by the seven strains through an in-vitro cell experiment, and revealing the activation and enhancement effects of the seven strains on immune cell functions. According to the invention, the immunotherapy effect of the non-small cell lung cancer patient can be promoted to be improved by combining a plurality of beneficial specific microorganisms in an airway administration mode. In conclusion, the method has a good application prospect.

The application provides a lung segment bronchus catheter, which comprises a catheter tail end ventilation and suction interface, a cuff inflation device, an outer tube, an inner tube, a front end cuff and a guide end formed by the inner tube; the cuff is annularly arranged on the outer surface of the catheter head, and is in the form of a ring ball wrapped around the inner tube in the inflated state; the cuff inflation interface and the cuff inflation conduit are communicated between the gap between the outer tube and the inner tube at the catheter tail and lead to the cuff; the catheter ventilation and suction interface is communicated with the inner tube and the guide end formed by the inner tube, and a guide wire is arranged in the catheter ventilation and suction interface to form a straight lumen. The catheter can enter the target lung segment or sub-lung segment bronchus through the operation channel of the bronchoscope, the inflated cuff seals the airway cavity around the lung segment bronchus catheter cavity, then the guide wire is pulled out from the lung segment bronchus catheter cavity, the target lung segment or sub-lung segment is inflated through the catheter ventilation and suction interface, so that the anatomical range of the target lung segment or sub-lung segment after ventilation is revealed, the technical problem that a thoracic surgeon cannot accurately identify the anatomical range of the target lung segment in the operation is effectively solved, and the thoracic surgery anatomical partial lobectomy operation is facilitated.

The present disclosure provides methods, uses, and pharmaceutical compositions with utility in the treatment of acute lung injuries or chronic lung diseases including, bronchopulmonary dysplasia and exacerbations of bronchopulmonary dysplasia.

The present invention provides a mutant adeno-associated virus serotype 1 (AAV1) capsid protein, wherein the mutant has an amino acid substitution at a specific position compared to the amino acid sequence of the wild-type AAV capsid protein; a nucleic acid encoding the mutant AAV1 capsid protein; a recombinant AAV1 vector comprising the nucleic acid encoding the mutant AAV1 capsid protein; and a pharmaceutical composition comprising the vector. In particular, a recombinant viral vector comprising the nucleic acid encoding the mutant AAV1 capsid protein enhances transgene expression in the lungs and bronchi when delivered in an aerosol state through the bronchi, making it useful for the prevention or treatment of respiratory diseases.

The present invention provides a lung bronchiole-microenvironment-mimetic biological tissue chip as a platform for testing the inhalation of chemical harmful substance, respiratory toxicity, and pulmonary disease drug efficacy.

This invention provides a liposomal sustained-release composition of a bronchodilator for treating lung diseases. The liposomal bronchodilator comprises liposomes encapsulating the bronchodilator. The bronchodilator is stably encapsulated in the liposomes, and the resulting liposomal bronchodilator has been shown to be stably nebulized or aerosolized for administration via inhalation to treat individuals in need.

The utility model relates to a melamine pulse batch-type purging separation device, the output end is connected with a pipeline system, the device comprises a branch air pipe, a flow deflector is arranged at the connecting position of the pipeline system and the branch air pipe, the flow deflector wraps the outlet of the branch air pipe and forms a flow guide cavity, the flow deflector comprises an arc-shaped part and a straight line part, and the arc-shaped part is connected with the straight line part. And the straight line part is parallel to the flow direction of gas in the pipeline system. According to the utility model, the valve is intermittently purged through the branch air pipe pulse, so that the interior of the valve body is ensured to be clean, and the valve acts freely and is closed tightly; meanwhile, the flow deflectors are arranged, the flow direction of gas can be changed, the gas is forced to be parallel to the linear part, and therefore the gas flowing out of the branch gas pipes and the gas flow direction in the pipeline system are the same, and the pulse effect of compressed gas can be reserved.

Described is a method for improving the condition of a patient suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), comprising administering to the patient by inhalation from 2.5 million international units (MIU) to 6 MIU of colistimethate sodium (CMS) once a day for a period of at least 28 days. Other embodiments are also disclosed.

The invention relates to the field of traditional Chinese medicines, in particular to novel application of a Sweeping Tianhu lung-clearing and cough-relieving composition in treatment of chronic obstructive pulmonary disease. Animal experiment studies show that the Sweetio lung-clearing and cough-relieving composition can significantly improve the lung function of COPD mice and inhibit bronchial abnormal remodeling. The action mechanism of the composition is related to inhibition of lung tissue cell apoptosis, alleviation of inflammatory cell infiltration and improvement of abnormal remodeling of bronchus, which indicates that the Sweeping Litu composition for clearing away lung-heat and relieving cough has obvious pharmacological activity of resisting COPD (chronic obstructive pulmonary disease).

The invention relates to medical uses of alvelestat, and pharmaceutically acceptable salts thereof, in the treatment of non-cystic fibrosis bronchiectasis.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

An implantable artificial bronchus (IAB) is provided that is used for the treatment of chronic obstructive pulmonary diseases, such as pulmonary emphysema. The implantable artificial bronchus can be made with silicone or nitinol, and has a tapered cylindrical shape. Additional embodiments of this apparatus may be further associated with a one-way valve on the nozzle of the IAB.

The invention relates to the field of biological medicine, in particular to a biomarker for diagnosing pneumonia. The invention provides application of a biomarker in preparation of a kit for diagnosing pneumonia and / or evaluating the curative effect of pneumonia, and is characterized in that the biomarker comprises ADA2 in bronchoalveolar lavage fluid, and the kit is used for quantitatively detecting the content of ADA2 in a bronchoalveolar lavage fluid sample of a subject. By detecting the content of ADA2 in a bronchoalveolar lavage fluid sample of a subject, whether the subject is a severe pneumonia patient or not can be quickly and accurately diagnosed.

The invention provides a budesonide inhalable solution composition and a preparation method thereof. Compared with an existing budesonide suspension preparation, the budesonide inhalable solution composition provided by the invention is stable in property; the budesonide and the terbutaline sulfate contained in the solution composition have excellent delivery performance and pharmacokinetic properties, can be better distributed on the surface of bronchus or lung, and can be quickly dissolved and absorbed, quickly exert efficacy and relieve asthma symptoms. The budesonide inhalable solution composition provided by the invention is simple in preparation method and easy for industrial production.

Aspects of the present disclosure provide compositions comprising NEK10 for example, wild-type NEK10 or a hyperactive NEK10 mutant such as NEK10S684D, and methods of using such for treating a respiratory disorder such as bronchiectasis.

The utility model relates to a system for eliminating, reducing, clearing and sucking sputum and treating waste sputum. The system comprises a sputum tank, a liquid medicine tank and a liquid tank. The inner cavity of the tank is connected with a positive-negative pressure air source, a water source and a sputum suction and drainage pipe. The device further comprises a foot switch, an electromagnetic valve, a pressure regulator, a controller, an electromagnetic vibrator, an expiration electromagnetic valve switch, a trachea cannula, a double-channel sputum suction tube and the like. According to the principle, during sputum excretion, resonance is generated during lung expiration of a patient by controlling the switching frequency of the electromagnetic valve and vibration of the vibrator in a timing mode, lung secretions continuously overflow, and the treatment effects of sputum excretion, inflammation diminishing and detoxification are achieved. During sputum suction, the sputum suction tube is inserted into a trachea and a bronchus within more than ten seconds, and a trace amount of liquid is used for reducing and clearing sputum and synchronously sucking sputum, so that the ventilation and oxygen supply effects are improved, and the sputum suction tube plays a crucial role in rescuing the life of a critically ill patient. Sucked sticky sputum is added with water, stirred and discharged into a sewage station, replacement and destruction of a sputum suction bottle are omitted, cross infection is prevented, and environment-friendly biological safety scientific management is facilitated.

The invention provides an indoor pathogen aerosol transmission risk quantitative evaluation and closed-loop control method, and relates to the technical field of public health environment engineering.The indoor pathogen aerosol transmission risk quantitative evaluation and closed-loop control method comprises the steps that multi-dimensional environment parameters such as spatial layout, ventilation operation parameters, pathogen characteristics, personnel activity and protection equipment parameters are obtained; obtaining an air concentration distribution field and a surface concentration distribution field through numerical calculation; respectively constructing dose calculation and dose response models of the contact path and the inhalation path, wherein the inhalation path divides the respiratory tract into at least an upper respiratory tract region, a tracheal bronchus region and a pulmonary alveolar region, and calculating a partitioned deposited dose; monte Carlo simulation is adopted to represent the randomness of key parameters, the contact infection probability, the inhalation infection probability and the comprehensive infection risk are output, a ventilation control set value or a control instruction meeting a risk threshold value is generated, and accurate evaluation and closed-loop control of the indoor pathogen aerosol transmission risk can be achieved.

The invention belongs to the technical field of biological electromagnetic measurement and imaging, and discloses a lung electrical impedance imaging physical model and a using method thereof.The lung electrical impedance imaging physical model comprises an elastic conductive simulated thorax, the elastic conductive simulated thorax is provided with a top cover and a bottom cover, and the top cover is connected with a simulated airway; the simulated airway comprises a first bronchial duct, a second bronchial duct and a third bronchial duct, the first bronchial duct penetrates through the top cover and is in sealed connection with the top cover, the second bronchial duct and the third bronchial duct are located in the elastic conductive simulated thorax, and the upper ends of the second bronchial duct and the third bronchial duct are both communicated with the lower end of the first bronchial duct; the lower ends of the second bronchial canal and the third bronchial canal are connected with simulated lungs, and conductive layers are arranged on the surfaces of the simulated lungs. The lung ventilation impedance change process can be simulated, and EIT equipment of different manufacturers can be compatible.

The application discloses a lung deep layer targeted delivery method and a micro robot cluster, and comprises the following steps: preparing microgel particles containing magnetic microparticles, developing particles and cargos, and combining the prepared microgel particles to obtain the micro robot cluster; controlling the motion, climbing and reconstruction of the micro robot cluster in a non-fluid environment to realize the motion in a pipe environment with holes; controlling the motion of the micro robot cluster in a lung sample under the guidance of X-ray to deliver the micro robot cluster to a target bronchus of the lung sample; or controlling the delivery of the micro robot cluster in a target lung under the guidance of computer tomography imaging, and releasing the wrapped cargos in the target bronchus; and the micro robot cluster can realize the targeted delivery in the lung environment full of air, the lung environment with a mucous layer and a target bronchus in the lung deep layer.

An inhalation powder containing 24.1 μg of glycopyrronium bromide and 12.7 μg of formoterol fumarate dihydrate per unit dose is disclosed. The powder shows a clear bronchodilatory effect in patients with COPD after twice daily administration. After repeated administration, the lung function of the patients is significantly improved.

Disclosed herein are compounds useful for treating obstructive lung diseases. The compounds are TAS2Rs agonists and may further be used to treat disorders and conditions implicated by TAS2R. In some instances the disclosed compounds can be used to treat asthma.